Hanne Rozema

Zoekresultaten

• 2019

  Role of disease modifying treatment in the risk of alloimmunization in transfused patients with myelodysplastic syndromes: A population-based study

  Rozema, H., Kibbelaar, R., Veeger, N., Hoogendoorn, M. & Van Roon, E., 13-nov.-2019, In: Blood. 134, Suppl. 1

  Onderzoeksoutput › Academic

  • Hemocyte 100%
  • Disease 100%
  • Myelodysplastic Syndrome 100%
  • Alloimmunization 100%
  • Blood Product 75%
• 2017

  Overall Survival, Initial Treatment And Treatment Duration Of Patients With Myelodysplastic Syndrome, A Detailed Population Based Study

  Rozema, H., Kibbelaar, R., Veeger, N., Van Roon, E. & Hoogendoorn, M., 26-jun.-2017, In: Haematologica. 102, blz. 490 1 blz.

  Onderzoeksoutput › Academic

  Open Access

  Bestand
  2463 Downloads (Pure)